Abstract
Antiplatelet autoantibodies that are produced as a result of B and T lymphocyte interactions are regarded to have a cardinal role in the pathogenesis of immune thrombocytopenia (ITP). In numerous autoimmune disorders, interleukin-21 (IL-21) is suggested to play an important role in the B cell stimulation by follicular helper T (TFH) and the enhancement of autoantibody production. The present study aimed to explore the levels of IL-21 in ITP patients who did not respond to first line treatment and had splenectomy as a second line therapy. Control group was comprised by patients who underwent splenectomy for other reasons than autoimmune or malignant hematological pathologies. Our results showed no significant difference in plasma levels of IL-21 between ITP patients and controls. Nevertheless, our data have clinically and scientifically important value, further investigations, considering previous treatments, refined controls and other research limitations, are needed to understand the detailed role of IL-21 in ITP pathogenesis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
